The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Prometheus
 
Zahra Rahman
No Relationships to Disclose
 
Yan Lin
No Relationships to Disclose
 
Priyanka Vallabhaneni
No Relationships to Disclose
 
Hussein Abdul-Hassan Tawbi
No Relationships to Disclose
 
Andrew Gnan
No Relationships to Disclose
 
Amanda McFadden
No Relationships to Disclose
 
Amy Rose
No Relationships to Disclose
 
Chelsea Pruckner
No Relationships to Disclose
 
Melissa Wilson
No Relationships to Disclose
 
James F. Pingpank
No Relationships to Disclose
 
Matthew Peter Holtzman
No Relationships to Disclose
 
Robert L. Ferris
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Merck; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; VentiRx
 
Uma N. M. Rao
No Relationships to Disclose
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; GreenPeptide; Roche
Research Funding - Merck (Inst); Prometheus (Inst)